NCT05518201View on ClinicalTrials.gov

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions
Penile CancerAnal CancerPIN-1PIN-2PIN-3AIN1AIN2AIN3Genital Wart
Interventions
BIOLOGICAL

Placebo among 18-45 yrs

Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).

BIOLOGICAL

Placebo among 9-17 yrs

Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).

Trial Locations (1)

Unknown

Center for Disease Control and Prevention, Mianzhu

All Listed Sponsors
lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY